Dr. Madduri on Treatment After CAR T Cells in Myeloma

Video

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after chimeric antigen receptor (CAR) T-cell therapy in patients with myeloma.

One of the biggest unmet needs in the myeloma treatment landscape is for the patients who need treatment after receiving CAR T cells, Madduri says, although there are strategies emerging in this setting. Most CAR T cell products are BCMA-directed, and BCMA antibody drug conjugates and other targeted therapies have been developed. An important question is whether the already penta-refractory patients who progress on CAR T cells have lost BCMA antigen, and if so, can they be treated with these other options? Research is still underway to better understand the mechanism of BCMA.

However, Madduri says, there is hope that CAR T cells will soon bring curative strategies to the treatment of these patients. Recently, at the 2018 ASH Annual Meeting, the anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3% with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.

Related Videos
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
© 2024 MJH Life Sciences

All rights reserved.